Interleukin 12: still a promising candidate for tumor immunotherapy?
Open accessThe DOI matches its Crossref record; 362 of the 362 references it cites were found in a registry or an index.
Abstract
Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities. However, despite encouraging results in animal models, very modest antitumor effects of IL-12 in early clinical trials, often accompanied by unacceptable levels of adverse events, markedly dampened hopes of the successful use of this cytokine in cancer patients. Recently, several clinical studies have been initiated in which IL-12 is applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). The near future will show whether this renewed interest in the use of IL-12 in oncology will result in meaningful therapeutic effects in a select group of cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous attempts to develop IL-12-based therapies for human use had severely toxic consequences (Lasek et al., 2014) likely due to systemic administration routes.”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Lasek et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5 retracted
(1999) · The FASEB Journal · doi:10.1096/fasebj.13.12.1575 · Cited by 152 · cited 1×
“[85], and TNF-mediated apoptosis of fibroblasts [86].”
RetractedThe IL-15Rα Chain Signals Through Association with Syk in Human B Cells
Bulanova, E., Budagian, V., Pohl, T., Krause, H., Dürkop, H., Paus, R., & Bulfone-Paus, S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6292 · Cited by 84 · cited 2×
“and dendritic cells in particular, simultaneously express the IL15Ra chain, which, in contrast to IL-2Ra, binds IL-15 with high affinity (Ka 10 11 M) [43] and can mediate signal transduction [44].”
BackgroundRetractedA promiscuous liaison between IL‐15 receptor and Axl receptor tyrosine kinase in cell death control
Budagian, V., Bulanova, E., Orinska, Z., Thon, L., Mamat, U., Bellosta, P., Basilico, C., Adam, D., Paus, R., & Bulfone‐Paus, S. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600874 · Cited by 75 · cited 2×
“On the other hand, both the IL-2/15b chain and a unique IL-15Ra chain signal through SYK protein tyrosine kinase of the SYK/ZAP-70 family [44,69], and IL-15Ra activates protein tyrosine kinase AXL [70].”
BackgroundRetractedBulanova, E., Budagian, V., Duitman, E., Orinska, Z., Krause, H., Rückert, R., Reiling, N., & Bulfone-Paus, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610036200 · Cited by 63 · cited 2×
“On the other hand, some soluble IL-15Ra isoforms released as a result of alternative splicing or proteolytic cleavage [57] could inhibit the activity of IL-15 [57,58], and tumor cells can release proteolytically cleaved IL-15Ra as one of their tumor evasion strategies [59].”
BackgroundRetractedReverse Signaling through Membrane-bound Interleukin-15
Budagian, V., Bulanova, E., Orinska, Z., Pohl, T., Borden, E. C., Silverman, R. H., & Bulfone‐Paus, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403182200 · Cited by 60
RetractedChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“In contrast to mice, human tumors seem to consist of much more heterogenous population of tumor cells, developed as a result of tumor escape mechanisms, and contain strongly immunosuppressive soluble and cellular components (including myeloid-derived suppressor cells) that are resistant to IL-12-induced antitumor acti…”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundDevelopment of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134 · cited 1×
“The main source of IL-12 in humans is the activated antigen-presenting cells, such as dendritic cells [4], especially of the CD1c+ phenotype [5], as well as the hematopoietic phagocytes (monocytes, macrophages, and also neutrophils) [6], but IL-12 can also be produced by other cell types [7, 8].”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Cited by
Items 301–400 of 550
Katkeviciutė, E., Bircher, A., Sanchez, R., Schwill, M., Dorst, A., Morsy, Y., Conde, J., Zamboni, N., Gademann, K., Scharl, M. M., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115357 · Cited by 12
Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12
Franks, S. E., Santiago-Sánchez, G. S., Fabian, K. P., Solocinski, K., Chariou, P. L., Hamilton, D. H., Kowalczyk, J. T., Padget, M. R., Gameiro, S. R., Schlom, J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03459-7 · Cited by 11
Lee, C.-H., Huang, W., Lee, K.-Y., Kuan, C., Wu, T., Sun, J., & Wang, T. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.150236 · Cited by 11
IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine
Mookerjee, A., Graciotti, M., & Kandalaft, L. E. (2019) · Cancers · doi:10.3390/cancers11010040 · Cited by 11
“However, DCs matured with this mixture failed to produce significant levels of interleukin-12 (IL-12) a crucial signal for T cell activation and Th1 differentiation [21].”
BackgroundCytokine Profile in Early Infection byLeptospira interrogansin A/J Mice
Bavia, L., de Castro, Í. A., Amano, M. T., da Silva, A. M. G., Vasconcellos, S. A., & Isaac, L. (2019) · Journal of Immunology Research · doi:10.1155/2019/1892508 · Cited by 11
“In addition, the reduction of IL-12 p40 subunit levels may lead to lower production of IL-12p70, since this cytokine is formed by the covalent attachment of p35 and p40 subunits [56, 57].”
Beyond antibiotics for pulmonary nontuberculous mycobacterial disease
WATERER, G. W. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000665 · Cited by 11
“There is still interest in IL-12 therapy in oncology [33], but no human studies in infectious diseases have been published.”
BackgroundZheng, Y., Lu, Z., Ding, J., Jiang, N., Wang, J., Yang, J., Song, J., Chen, H., Fang, L., Li, H., et al. (2022) · Cancers · doi:10.3390/cancers14184512 · Cited by 11
Nascimento, C. S., Carvalho, J. G., Tavares, N. C., Lage, A. C. P., Pascoal-Xavier, M. A., de Melo, C. P., Alves, É. A. R., & Calzavara-Silva, C. E. (2025) · Cancer Nanotechnology · doi:10.1186/s12645-025-00323-4 · Cited by 10
“This cascade drives the expression of ferritin and promotes an M1-like macrophage profile, characterized by increased expression of CD86, TNF-α, pro-inflammatory cytokines, and ROS, all of which promote tumor cell apoptosis (Lasek et al. 2014).”
A virus based vaccine combined with IL12 gene therapy eradicates aggressive melanoma
Brišar, N., Šuster, K., Kranjc, S., & Cör, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-04026-z · Cited by 10
“The literature presents evidence supporting the immune-activating effects of IL-12, which include enhancing the cytotoxicity of CD8 + T lymphocytes, promoting the differentiation of CD4 + T lymphocytes into Th1 cells, and stimulating IFNγ production 44 .”
Store-Operated Ca 2+ Entry in Fibrosis and Tissue Remodeling
Abdelnaby, A. E., & Trebak, M. (2024) · Contact · doi:10.1177/25152564241291374 · Cited by 10
“SOCE can in fl uence macrophage polarization indirectly by modulating the production of IL-13 and IL-4 by different T-cell subsets as discussed earlier, thereby playing a crucial role in immune response regulation.”
InfluentialJiang, H., Nace, R. A., Ferguson, C., Zhang, L., Peng, K. W., & Russell, S. J. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101874 · Cited by 10
“51,52 To incorporate IL-12 in a more controlled manner, we integrated the single-chain IL-12 (scIL12) gene driven by the pTight promoter into the backbones of AD169r-BAC-R13.”
Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma
Dollin, Y., Rubin, J., Carvajal, R. D., Rached, H., & Nitzkorski, J. R. (2020) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2020.11.063 · Cited by 10
“The main anti-tumor properties of IL-12 include: inhibiting angiogenesis, increasing the activation and survival of memory T-cells allowing for adaptive immunity, and inhibiting T regulatory cells and TH2 cells.”
BackgroundBozic, T., Serša, G., Kranjc, S., Čemažar, M., & Markelc, B. (2021) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2021.107795 · Cited by 10
Singh, M., & Venkatas, J. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220609115109 · Cited by 10
Kuijpers, T., & Blom, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113651 · Cited by 10
Synthesis, Characterization, and In Vivo Cytokinome Profile of IL-12-Loaded PLGA Nanospheres
Lacinski, R. A., Markel, J., Noore, J., Pratt, H. G., & Lindsey, B. A. (2022) · Journal of Immunology Research · doi:10.1155/2022/6993187 · Cited by 10
“…clinical use of recombinant IL-12 systemically has been complicated by inadvertent overstimulation in the form of systemic in fl ammatory response syndrome (SIRS) and T cell exhaustion (TCE) [12], as high loading doses of free protein were needed to ensure adequate distribution to target tissues.”
Wang, Y., Liu, C., Zhang, N., Song, X., Song, Y., Cai, D., Fang, K., & Chang, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113289 · Cited by 10
Valenzuela-Cardenas, M., Fisher, C., Bartee, M. Y., & Bartee, E. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200866 · Cited by 9
“…including hematopoietic issues such as leukopenia, anemia, neutropenia, and decreased platelets and clotting ability, known as thrombocytopenia, 11 – 13 and hepatocellular damage, commonly presenting as increased liver enzymes, like alanine aminotransferase (ALT) and aspartate transaminase…”
Immunotherapy for Recurrent Glioma—From Bench to Bedside
Pu, Y., Zhou, G., Zhao, K., Chen, Y., & Shen, S. (2023) · Cancers · doi:10.3390/cancers15133421 · Cited by 9
“IL-12 functions mainly by increasing IFN-γ secretion and shifting CD4+ T cells to a Th1 phenotype [70].”
BackgroundDinutuximab in the Treatment of High-Risk Neuroblastoma in Children
Gür, H., Özen, F., Saylan, C. C., & Atasever-Arslan, B. (2017) · Clinical Medicine Insights Therapeutics · doi:10.1177/1179559x17719106 · Cited by 9
Li, C., Creasy, T. H., Pilataxi, F., Greenlees, L. M., Vence, L. M., Sridhar, S., & Streicher, K. L. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03065-5 · Cited by 9
Li, P., Zhang, H., Ji, L., & Wang, Z. (2020) · Medical Science Monitor · doi:10.12659/msm.923855 · Cited by 9
“Given that IL-2 can enhance the activity of NK cells on cell lysis, cytolytic T-cell response, and secretion of IFN-g from both types of cells [1,2], a clinical trial using IL-12 combined with an anti-CD20 antibody (rituximab) was conducted with patients with refractory NHL [18].”
BackgroundIntratumoral delivery of 4-1BBL boosts IL-12-triggered anti-glioma immunity
Lunavat, T. R., Nieland, L., van de Looij, S. M., de Reus, A. J. E. M., Couturier, C., Farran, C. A. E., Miller, T. E., Lill, J. K., Schübel, M., Xiao, T., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.028 · Cited by 9
“Besides affecting DCs, IL-12 and 4-1BBL have been suggested to activate CD8 POS T cells, 93 resulting in the release of cytotoxic molecules, such as granzymes, 94 and can also support other immune cells, such as NK cells 95,96 and regulatory/helper cells.”
Click-to-Release for Controlled Immune Cell Activation: Tumor-Targeted Unmasking of an IL12 Prodrug
den Brok, M. H., de Roode, K. E., Zijlmans, L. H. M., Kleijn, L. H. J., van Stevendaal, M. H. M. E., Versteegen, R. M., Wouters, L. W. M., Rossin, R., & Robillard, M. S. (2025) · Pharmaceuticals · doi:10.3390/ph18091380 · Cited by 8
“Furthermore, IL12 promotes the differentiation of CD4+ T cells into T helper 1 (Th1) cells and enhances antibody-dependent cellular toxicity [2,4,8].”
Hu, H., Yuan, S., Fu, Y., Li, H., Xiao, S., Gong, Z. H., & Zhong, S. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-215 · Cited by 8
“IL-12 is a multipotent cytokine encoded by IL12B that has been shown to be effective in anti-tumor therapy (46) .”
Han, S., Oh, J. S., & Kim, J. S. (2020) · Annals of Nuclear Medicine · doi:10.1007/s12149-020-01537-9 · Cited by 8
Remic, T., Serša, G., Levpuscek, K., Tratar, U. L., Uršič, K., Cör, A., & Kamenšek, U. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.974912 · Cited by 8
Hazra, R., Chattopadhyay, S., Mallick, A., Gayen, S., & Roy, S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02416-3 · Cited by 8
“It is chiefly generated by activated antigen-presenting cells, like dendritic cells (DCs) and hematopoietic phagocytes [141].”
Nazeam, J. A., El-Hefnawy, H. M., & Singab, A. N. B. (2020) · Journal of Medicinal Food · doi:10.1089/jmf.2019.0230 · Cited by 8
“23 IFN-a has emerged as the most clinically useful IFN, where it could induce expression of major histocompatibility complex class I molecules on tumor cells.”
Ragoonanan, D. S., Sheikh, I. N., Gupta, S. K., Khazal, S. J., Tewari, P., Petropoulos, D., Li, S., & Mahadeo, K. M. (2022) · Biomedicines · doi:10.3390/biomedicines10092286 · Cited by 8
“However, researchers have demonstrated that through dose de-escalation and modification of dose scheduling, such toxicities can be mitigated [92].”
BackgroundRole of Cytokines in Tumor Immunity and Immune Tolerance to Cancer
Murugaiyan, G. (2014) · Springer eBooks · doi:10.1007/978-3-662-44006-3_7 · Cited by 8
Lu, C., Hu, L., Hu, C., Liu, J., Li, B., Liao, X., Zhou, J., Liu, S., Li, Y., Yuan, D., et al. (2021) · BioMed Research International · doi:10.1155/2021/8865601 · Cited by 8
“IL12, a cytokine with a wide range of biological activities, is mainly produced by activated inflammatory cells [28].”
BackgroundImmunotherapeutic Approaches in Cancer
Keshavarz‐Fathi, M., & Rezaei, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814039-0.00002-3 · Cited by 8
Sheinin, M., Mondal, S., & Pahan, K. (2023) · Cancers · doi:10.3390/cancers15245796 · Cited by 7
“Recently, studies have shown that immunotherapy is a worthwhile approach, which can enhance the immune system’s capacity to identify and kill cancer cells [4,5].”
BackgroundCytokine Biopharmaceuticals with “Activity-on-Demand” for Cancer Therapy
Rotta, G., Puca, E., Cazzamalli, S., Neri, D., & Plaza, S. D. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00187 · Cited by 7
Weiss, L., Schluck, M., Classens, R., de Jonge, P. K. J. D., van der Waart, A. B., Nguyen, K. G., Nguyen, T. T., Zaharoff, D. A., Malmberg, K., Dolstra, H., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.11.012 · Cited by 7
Improving IL12 immunotherapy in glioblastoma by targeting the long noncoding RNA INCR1
Saini, S., Gadet, J. A. M. A., Freeman, G. J., Chiocca, E. A., & Mineo, M. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-04978-2 · Cited by 7
“IL12 enhances natural and adaptive immunity, potently stimulates the production of interferon-gamma (IFNγ) through activating NK cells and cytotoxic T cells, and alters the tumor microenvironment [12].”
Liebl, K., Aschenbrenner, I., Schiller, L., Kerle, A., Protzer, U., & Feige, M. J. (2023) · Molecular Immunology · doi:10.1016/j.molimm.2023.08.010 · Cited by 7
Dai, L., Jing, Z., Zhu, Y., Deng, K., & Ma, L. (2023) · PubMed Central · Cited by 7
Liao, J., Wu, Z., Qiu, Y., Xue, F., Gong, K., Duan, Y., Xu, C., Liu, B., Lin, J., Dong, Y., et al. (2024) · Science China Materials · doi:10.1007/s40843-024-3001-3 · Cited by 7
“However, it is noteworthy that systemic administration of IL-12 has been demonstrated to be excessively toxic which limits its clinical application [24–27].”
Targeting PD-1+ T cells with small-format immunocytokines enhances IL-12 antitumor activity
Silva-Pilipich, N., Beloki, U., Apaolaza, P., Igea, A., Salaberry, L., Prats-Mari, L., Rovira, E., Ondiviela, M., Gorraiz, M., Lasarte, J. J., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.027 · Cited by 7
Nanoparticles co-delivering pVSVMP and pIL12 for synergistic gene therapy of colon cancer
Xiao, Y., Yang, Y., Wu, Y., Wang, C., Cheng, H., Zhao, W., Li, Y., Liu, B., Long, J., Guo, W., et al. (2017) · RSC Advances · doi:10.1039/c7ra03727a · Cited by 7
Optical Control of Cytokine Signaling via Bioinspired, Polymer-Induced Latency
Perdue, L. A., Do, P., David, C., Chyong, A., Kellner, A. V., Ruggieri, A. N., Kim, H. R., Salaita, K. S., Lesinski, G. B., Porter, C. C., et al. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00264 · Cited by 7
Sánchez-Arribas, N., Martínez‐Negro, M., Aicart-Ramos, C., de Ilarduya, C. T., Aicart, E., Guerrero‐Martínez, A., & Junquera, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050729 · Cited by 7
“Many IL-12 delivery strategies have been successfully carried out in different animal models [18,19].”
BackgroundZhang, C.-G., Yeh, C.-Y., Hsu, S.-Y., Prakash, M., Abarientos, A. B., Chiang-Hsieh, H.-M., Lin, Y., Ortiz, C. L. D., Yang, L., Liang, P., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03756-6 · Cited by 6
A non-lipid nucleic acid delivery vector with dendritic cell tropism and stimulation
Kim, H. S., Halabi, E. A., Enbergs, N., Köhler, R. H., Fei, F., Garris, C., & Weissleder, R. (2024) · Theranostics · doi:10.7150/thno.95267 · Cited by 6
“[40 ‑ 43].”
Overcoming intratumoral transport barriers: Advances in local immunotherapy delivery platforms
Deeson, M. A., Chua, C. Y. X., & Grattoni, A. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115888 · Cited by 7
Role of Cytokines in Tumor Immunity and Immune Tolerance to Cancer
Garo, L. P., & Murugaiyan, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-30845-2_13 · Cited by 6
Role of cytokines in hepatocellular carcinoma
Aghayev, T., Titerina, E. K., Хорева, М. В., & Gankovskaya, L. V. (2022) · Medical Immunology (Russia) · doi:10.15789/1563-0625-roc-2512 · Cited by 6
Clinical Trials with IL-12 in Cancer Immunotherapy
Lasek, W., & Zagożdżon, R. (2016) · SpringerBriefs in immunology · doi:10.1007/978-3-319-46906-5_3 · Cited by 6
Self-citationCommon shared genetic variation behind decreased risk of breast cancer in celiac disease
Ugalde‐Morales, E., Li, J., Humphreys, K., Ludvigsson, J. F., Yang, H., Hall, P., & Czene, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-06287-9 · Cited by 6
Nemati, M., Ebrahimi, H.-A., Hajghani, H., Khosravimashizi, A., & Jafarzadeh, A. (2018) · Archives of Neuroscience · doi:10.5812/archneurosci.63360 · Cited by 6
“IL-12 induces the generation of Th1 cells characterized by the secretion of cytokines such as IFN-γ, IL-2, and TNF-α (12).”
BackgroundInfluentialHong, J., & Yun, C. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.01.009 · Cited by 6
Kamenšek, U., Renčelj, A., Jesenko, T., Remic, T., Serša, G., & Čemažar, M. (2021) · Heliyon · doi:10.1016/j.heliyon.2022.e08879 · Cited by 6
Chrestella, J., Farhat, F., Daulay, E. R., Asnir, R. A., Yudhistira, A., & Nasution, I. A. (2018) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2018.356 · Cited by 6
Biopharmaceuticals and Gene Vectors Opening New Avenues in Cancer Immune Therapy
Sami, H., & Ogris, M. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0032 · Cited by 6
Analysis of Changes in Plasma Cytokine Levels in Response to IL12 Therapy in Three Clinical Trials
Schwarz, E. J., Benner, B. N., Yu, L., Tounkara, F., & Carson, W. E. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0122 · Cited by 5
Zhao, F. H., Gong, L., Wang, P., Chen, D., Cao, S., Yang, F., Tang, M., Meng, Y., Wang, Y., Miao, L., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03425-8 · Cited by 5
“For example, IL-12 demonstrated high toxicity in a phase II trial involving intravenous administration, tragically leading to the fatalities of two out of seventeen patients [10].”
Lv, J., Zhu, W., Xie, X., Tian, C., Zhu, C., Hu, Z., Li, Y., Shao, M., Liu, W., Ma, D., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.168033 · Cited by 5
Peters, C. W., & Nigim, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169051 · Cited by 5
“Similar to the systemic use of checkpoint inhibitors and BiTEs, IL-2 and IL-12 use in humans has been limited by toxicity [67,68], and for IL-2’s expansion of suppressive TREG cells.”
BackgroundFarahavar, G., Abolmaali, S. S., Biabanikhankahdani, R., & Tamaddon, A. M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104691 · Cited by 5
Kimura, R., Yamano, T., Onishi, U., Lyu, X., Nagamori, K., Le, T. V., Nakada, M., & Hanayama, R. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2509969 · Cited by 5
“…a key cytokine for th1 differentiation, plays important roles in tumor immune responses (trinchieri 2003; Knutson and Disis 2005). however, the application of il-12 in cancer immuno-therapy has been limited by its toxicity and moderate anti-tumor effects (Portielje et al. 2003; lasek et al. 2014).”
Ryapolova, A., Zinovieva, M., Vorona, K., Krapivin, B., Moroz, V., Gasanov, N. B., Иматдинов, И. Р., Imatdinov, A. R., Ivanov, R. A., Karabelsky, A. V., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178567 · Cited by 5
“…showed that both IL-12 and GM-CSF stimulate potent anti-tumor responses: IL-12 activates IFN-γ production in NK, CD4 + , and CD8 + T lymphocytes and induces T-helper 1 (Th1) differentiation [43–46], while GM-CSF promotes the maturation and activation of cross-presenting dendritic cells (DCs) [47].”
Chali, S. P., Kang, J., Fichter, M., Speth, K. R., Mailänder, V., & Landfester, K. (2024) · Advanced Science · doi:10.1002/advs.202403668 · Cited by 5
Lorenzo, C., Pérez-Chacón, G., Garaulet, G., Mallorquín, Z., Zapata, J. M., & Rodríguez, A. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.53 · Cited by 5
Zabrodskii, P. F., Maslyakov, V. V., & Громов, М. С. (2016) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-016-3508-x · Cited by 5
“The DDVP-induced suppression of B cell function , as well as the role of α7nAChR activation in this effect due to exposure of B cells to OPC and/or acetylcholine, was also proved by decreased blood concentration of IL-10 and IL-12, that are synthesized predominantly by B cells upon administration of T-independent Vi-A…”
BackgroundTherapeutic Potentials of IL-10 versus IL-12
Bhurani, V., & Dalai, S. K. (2018) · InTech eBooks · doi:10.5772/intechopen.76914 · Cited by 5
“Thus, the entire tumor microenvironment is affected by IL-12 in a variety of ways [31].”
BackgroundYang, J., Guo, R., Yan, D., Lu, H., Zhang, H., Ye, P., Jin, L., Diao, H., & Li, L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00335 · Cited by 5
“Interleukin 12 is a cytokine that is naturally produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation and is still a promising candidate for tumor immunotherapy (Lasek et al., 2014).”
BackgroundSafety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic
Savid-Frontera, C., Viano, M. E., Baez, N. S., Reynolds, D. A., Matellon, M., Young, H. A., & Rodriguez‐Galán, M. C. (2021) · Immunotherapy · doi:10.2217/imt-2021-0080 · Cited by 5
Secretory co-factors in next-generation cellular therapies for cancer
Okuma, A., Ishida, Y., Kawara, T., Hisada, S., & Araki, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907022 · Cited by 5
“Local recombinant IL-12 delivery can reshape the immunosuppressive TME (67, 68) and several clinical trials for tumor therapies with recombinant IL-12 administration have been conducted in recent decades (69).”
BackgroundJiang, H., Nace, R. A., Carrasco, T. F., Zhang, L., Peng, K. W., & Russell, S. J. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008307 · Cited by 5
“…B16- F10-nectin1 model (figure 6A), intratumoral administration of the Ellen-Δ ORF8- tet- off-scIL12 virus demonstrated superior efficacy in inhibiting tumor growth of both injected and uninjected tumors, thereby extending animal survival in comparison to the Ellen-Δ ORF8 virus (figure 6C,D).”
ResultSilva, B. D. O., Correia, N. A. A., de Barros, F. T., de Lima, L. P. O., Morais, A., Hassan, R., Dellalibera, E., Cavalcanti, M. D. S. D. M., & Muniz, M. T. C. (2019) · Tumor Biology · doi:10.1177/1010428319860400 · Cited by 5
Richter, L., Kropp, S., Proksch, P., & Scheu, S. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115145 · Cited by 5
Assim, M. M., & Saheb, E. J. (2020) · Iranian Journal of Parasitology · doi:10.18502/ijpa.v15i4.4850 · Cited by 5
“based immunotherapy may be more efficient in cancer patients with defects in IL-12 production (39, 40).”
BackgroundLeleux, J. A., Albershardt, T. C., Reeves, R. S., James, R. D., Krull, J. E., Parsons, A. J., ter Meulen, J., & Berglund, P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259301 · Cited by 5
“However, its potency has made recombinant IL-12 therapy challenging to apply successfully in the clinic, particularly in the context of systemic administration [11].”
BackgroundInnate and Adaptive Immune Responses to Cancer
Rausch, M. P., & Hastings, K. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-15935-1_5 · Cited by 5
Gupta, V., Kalia, N., Yadav, M., Noyes, A., Good, J., Hendricks, R., & Xu, W. (2018) · Bioanalysis · doi:10.4155/bio-2018-0083 · Cited by 5
El-Shemi, A. G., Ashshi, A. M., Na, Y., Li, Y., Basalamah, M. A., Al-Allaf, F. A., Oh, E., Jung, B., & Yun, C. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0365-4 · Cited by 5
Design of novel synthetic promoters to tune gene expression in T cellsPreprint
Bonfá, G., Martino, G., Sellitto, A., Rinaldi, A., Tedeschi, F., Caliendo, F., Melchiorri, L., Perna, D., Starkey, F., Nikolados, E.-M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.09.632034 · Cited by 5
Mangolini, M., Srivastava, S., Souster, E., Yang, Y., Wang, H., Karattil, R., Schultz, L., Ma, B., Pombal, D., Greenig, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.10.632392 · Cited by 5
Lawal, H. A., Raji, A. O., Olayiwola, A. E., Suleiman, Z. A., Muiz, W., Lawal, A. O., Okesanya, O. J., Ibrahim, R. B., & Oso, T. A. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001352 · Cited by 4
Zhang, J., Gao, W., & Ma, G. (2025) · Biomaterials Science · doi:10.1039/d5bm00848d · Cited by 4
Application of CAR-T therapy in solid tumors: current opportunities and challenges
Wang, A., Ye, X., Zhao, Y., Huang, D., & Zhang, C. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01033-8 · Cited by 4
“…limitation is the response kinetics; transcriptional circuits, such as the synNotch system, typically require several hours to induce the expression of the secondary CAR, creating a “ lag phase ” that may allow rapidly proliferating tumors to escape control or delay therapeutic onset [106, 108].”
Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy
Cotra, S., Kohandel, M., & Przedborski, M. (2024) · Biomolecules · doi:10.3390/biom14121513 · Cited by 4
A multidimensional analysis and future perspectives of cellular cancer vaccines
Li, X., Song, R., Zhu, J., He, J. B., & Liu, X. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152380 · Cited by 4
Safety and Pharmacokinetics of Intravesical Chitosan/Interleukin-12 Immunotherapy in Murine Bladders
Nguyen, K. G., Wagner, E. S., Vrabel, M. R., Mantooth, S. M., Meritet, D., & Zaharoff, D. A. (2021) · Bladder Cancer · doi:10.3233/blc-211542 · Cited by 4
Seaver, K., Kourko, O., Gee, K., Greer, P. A., & Basta, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884827 · Cited by 4
“IL-12 has been explored as a cancer vaccine adjuvant by promoting anti-tumor effects (30, 91), however, the use of IL-12 has been limited due to toxicity concerns (92, 93).”
BackgroundZare, H., Sanaei, M., Yazdi, M. H., & Shahverdi, A. R. (2023) · BioNanoScience · doi:10.1007/s12668-023-01133-x · Cited by 4
“Moreover, it is known as an anti-angiogenic factor and a possible anti-cancer drug [25].”
BackgroundNanosphere pharmacodynamics improves safety of immunostimulatory cytokine therapy
Lacinski, R. A., Dziadowicz, S. A., Stewart, A., Chaharbakhshi, E. O., Akhter, H., Pisquiy, J. J., Victory, J. H., Hardham, J. B., Chew, C., Prorock, A. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108836 · Cited by 4
Zhang, Z. (2024) · American Journal of Cancer Research · doi:10.62347/iaro1564 · Cited by 4
“Additionally, there’s evidence supporting IL-12’s capacity to enhance antigen presentation and improve tumor cell targeting [29, 30].”
BackgroundDevasia, A. G., Shanmugham, M., Ramasamy, A., Bellanger, S., Parry, L. J., & Leo, C. H. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116507 · Cited by 4
Dellalibera-Joviliano, R., Garcia, M. E., Marins, M., Fachin, A. L., Couto, L. B., Mesquita, E., Komoto, T. T., Silva, G., Neto, W. C., Orlando, L. C., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155625 · Cited by 4
Henmi, T., Matsuoka, H., Katayama, N., & Saito, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312794 · Cited by 4
Association of Interleukin-12A Genotypes With Nasopharyngeal Carcinoma Risk
Chen, K., Hsu, C.-L., Hsu, S.-W., Liu, Y.-F., WANG, Y.-C., SHIH, H.-Y., CHANG, W.-S., Bau, D., & Tsai, C.-W. (2025) · Anticancer Research · doi:10.21873/anticanres.17604 · Cited by 4
“Interleukin ‑ 12 (IL ‑ 12) is a critical immunoregulatory cytokine that bridges innate and adaptive immune mechanisms (10).”
Interleukin-12 in patients with cancer is synthesized by peripheral helper T lymphocytes
Michelin, M. A., Montes, L. N., Nomelini, R. S., Abdalla, D. R., Aleixo, A., & Murta, E. F. C. (2015) · Oncology Letters · doi:10.3892/ol.2015.3470 · Cited by 4
“The anticancer immune response in a number of types of cancer is mediated by IL‑12 (8), which may therefore be a candidate for use in tumor immunotherapy, due to its capacity to active the innate and adaptive immune responses (9).”
Intratumoral expression using a NFkB-based promoter enhances IL12 antitumor efficacy
Garaulet, G., Pérez-Chacón, G., Iniesta, H. A., Alfranca, A., Mulero, F., Martinez-Torrecuadrada, J. L., Zapata, J. M., & Rodríguez, A. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-018-0076-4 · Cited by 5
Interleukin‐12 sustained release system promotes hematopoietic recovery after radiation injury
Lin, C., Xiang, Y., Zhang, Y., Yang, Z., Chen, N., Zhang, W., Hu, L., Chen, J., Luo, Y., Wang, X., et al. (2024) · MedComm · doi:10.1002/mco2.704 · Cited by 3
“18 Accumulated studies have documented that a single administration of IL-12 can improve survival in murine and rhesus monkey models after lethal irradiation.”
BackgroundGao, Y., Zou, Y., Wu, C., Tao, J., Nie, Z., Yan, J., Wang, P., & Huang, X. (2025) · Virology Journal · doi:10.1186/s12985-025-02758-y · Cited by 3
“For instance, IL-12 acts largely through downstream IFN-γ induction [5, 6], making it less suitable for side-by-side comparison with IFN-γ itself in efforts to deconvolute cytokine-specific effects.”
Localized Immune Cascade Programming in Desmoplastic Tumors: In Silico Modeling and Validation Study
Novruzov, M., Mammadova, M., Raval, K. Y., Khan, W. U., & Shiraliyeva, U. (2026) · JMIRx Bio · doi:10.2196/85507 · Cited by 3
Effect of IL-7 and IL-15 on T cell phenotype in myelodysplastic syndromes
Dong, W., Ding, T., Wu, L., Ren, X., Epling‐Burnette, P. K., & Yang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.8459 · Cited by 3
“IL-15 is produced by numerous cell types in the context of an immune response, but primarily by members of the monocyte/macrophage lineage [14].”
Background
Metadata
- Authors
- Lasek, W., Zagożdżon, R., & Jakobisiak, M.
- Affiliations
- Medical University of Warsaw (PL)
- Corresponding author
- Lasek, Witold
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2014-02-11
- Volume
- 63
- Issue
- 5
- Pages
- 419-435
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC3994286
- OpenAlex
- W2025459290
- Cited by
- 495
- References
- 354
- Citations by year
- 2026: 23 · 2025: 40 · 2024: 42 · 2023: 49 · 2022: 52 · 2021: 53 · 2020: 64 · 2019: 41 · 2018: 33 · 2017: 32 · 2016: 33 · 2015: 21 · 2014: 7
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Commission (316254)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- IL-12, cancer immunotherapy, cancer vaccines, gene therapy, immunocytokines, natural killer cells, cytotoxic T lymphocytes, antitumor immunity
- MeSH terms
- Animals, Humans, Immunotherapy, Neoplasms, Genetic Therapy, Interleukin-12, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.